Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Giacomo Boffa, L. Massacesi, M. Inglese, A. Mariottini, M. Capobianco, L. Moiola M.P. Amato, S. Cottone, F. Gualandi, M. De Gobbi, R. Greco, R. Scimè, J. Frau, G. Bosco Zimatore, A. Bertolotto, G. Comi, A. Uccelli, A. Signori, E. Angelucci, C. Innocenti, F. Ciceri, A.M. Repice, M.P Sormani, R. Saccardi, G. Mancardi on behalf of the Italian BMT-MS study group

Neurology Publish Ahead of Print DOI: 10.1212/WNL.0000000000011461

Selezionato dal Lettore: Miryam Cannizzaro - Ospedale San Raffaele, Dipartimento di Neurologia, Milano

MOTIVATION: It is a multicentre, retrospective study aimed to determine whether HSCT can prevent long-term disability worsening in a large cohort of patients with aggressive MS. Authors collected data from 1997 to 2019 and showed an increase of disability worsening free survival (both in patients with RRMS and SPMS), together with an EDSS reduction in the RRMS patients’ group. 

I’ve chosen this study because it provides Class IV evidence that HSCT induces durable disease remission in most patients with an aggressive phenotype.